MYCAMINE

LOE Approaching

micafungin sodium

Astellas
NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
5

Mechanism of Action

[see Microbiology ()] .

Indications (6)

Acute Disseminated CandidiasisAbscesses in adultUse in Specific Populations ()]Esophageal Candidiasis in adultolderAbscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age

Clinical Trials (5)

NCT02678598N/ACompleted

A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Started Mar 2015
2,555 enrolled
Invasive Fungal Infections
NCT02127788N/ACompleted

Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology

Started Jul 2014
150 enrolled
Antifungal ProphylaxisHaemopathy
NCT00794703Phase 3Completed

A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections

Started Nov 2008
288 enrolled
FungemiaFungal Infections
NCT00608335Phase 1Completed

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Started Oct 2007
84 enrolled
Oropharyngeal CandidiasisCandidemiaInvasive Candidiasis+1 more
NCT00607763Phase 1Completed

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Started Oct 2007
9 enrolled
Invasive CandidiasisEsophageal CandidiasisOropharyngeal Candidiasis+1 more
Company
Astellas
Astellas
China - Shenyang
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers